ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?

by Rita Mejzini, Rita Mejzini, Loren L. Flynn, Loren L. Flynn, Loren L. Flynn, Ianthe L. Pitout, Ianthe L. Pitout, Ianthe L. Pitout, Sue Fletcher, Sue Fletcher, Sue Fletcher, Steve D. Wilton, Steve D. Wilton, Steve D. Wilton, P. Anthony Akkari, P. Anthony Akkari, P. Anthony Akkari
Published 2019-12-01

Altered Gut Microbiome in Parkinson’s Disease and the Influence of Lipopolysaccharide in a Human α-Synuclein Over-Expressing Mouse Model

by Anastazja M. Gorecki, Anastazja M. Gorecki, Leah Preskey, Leah Preskey, Megan C. Bakeberg, Megan C. Bakeberg, Jade E. Kenna, Jade E. Kenna, Christi Gildenhuys, Christi Gildenhuys, Gabriella MacDougall, Gabriella MacDougall, Sarah A. Dunlop, Sarah A. Dunlop, Frank L. Mastaglia, Frank L. Mastaglia, P. Anthony Akkari, P. Anthony Akkari, P. Anthony Akkari, Frank Koengten, Frank Koengten, Ryan S. Anderton, Ryan S. Anderton, Ryan S. Anderton
Published 2019-08-01

Single Nucleotide Polymorphisms Associated With Gut Homeostasis Influence Risk and Age-at-Onset of Parkinson's Disease

by Anastazja M. Gorecki, Anastazja M. Gorecki, Megan C. Bakeberg, Megan C. Bakeberg, Frances Theunissen, Frances Theunissen, Jade E. Kenna, Jade E. Kenna, Madison E. Hoes, Abigail L. Pfaff, Abigail L. Pfaff, P. Anthony Akkari, P. Anthony Akkari, P. Anthony Akkari, Sarah A. Dunlop, Sarah A. Dunlop, Sulev Kõks, Sulev Kõks, Frank L. Mastaglia, Frank L. Mastaglia, Ryan S. Anderton, Ryan S. Anderton, Ryan S. Anderton, Ryan S. Anderton
Published 2020-11-01

Novel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype

by Frances Theunissen, Frances Theunissen, Ryan S. Anderton, Ryan S. Anderton, Ryan S. Anderton, Frank L. Mastaglia, Frank L. Mastaglia, Loren L. Flynn, Loren L. Flynn, Loren L. Flynn, Samantha J. Winter, Samantha J. Winter, Ian James, Richard Bedlack, Stuart Hodgetts, Stuart Hodgetts, Sue Fletcher, Sue Fletcher, Steve D. Wilton, Steve D. Wilton, Steve D. Wilton, Nigel G. Laing, Mandi MacShane, Merrilee Needham, Merrilee Needham, Merrilee Needham, Ann Saunders, Alan Mackay-Sim, Alan Mackay-Sim, Ze’ev Melamed, Ze’ev Melamed, John Ravits, Don W. Cleveland, Don W. Cleveland, Don W. Cleveland, P. Anthony Akkari, P. Anthony Akkari, P. Anthony Akkari, P. Anthony Akkari
Published 2021-03-01

TOMM40 ‘523’ poly-T repeat length is a determinant of longitudinal cognitive decline in Parkinson’s disease

by Megan C. Bakeberg, Anastazja M. Gorecki, Abigail L. Pfaff, Madison E. Hoes, Sulev Kõks, P. Anthony Akkari, Frank L. Mastaglia, Ryan S. Anderton
Published 2021-07-01

The TOMM40 ‘523’ polymorphism in disease risk and age of symptom onset in two independent cohorts of Parkinson’s disease

by Megan C. Bakeberg, Madison E. Hoes, Anastazja M. Gorecki, Frances Theunissen, Abigail L. Pfaff, Jade E. Kenna, Kai Plunkett, Sulev Kõks, P. Anthony Akkari, Frank L. Mastaglia, Ryan S. Anderton
Published 2021-03-01